Extended Data Fig. 3: ALLO-715 in-vivo expansion by Dose Level in Patients Who Received a Fludarabine/Cyclophosphamide/ALLO-647 (FCA) Containing Lymphodepletion Regimen by Days Relative to CAR Dosing. | Nature Medicine

Extended Data Fig. 3: ALLO-715 in-vivo expansion by Dose Level in Patients Who Received a Fludarabine/Cyclophosphamide/ALLO-647 (FCA) Containing Lymphodepletion Regimen by Days Relative to CAR Dosing.

From: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

Extended Data Fig. 3: ALLO-715 in-vivo expansion by Dose Level in Patients Who Received a Fludarabine/Cyclophosphamide/ALLO-647 (FCA) Containing Lymphodepletion Regimen by Days Relative to CAR Dosing.The alternative text for this image may have been generated using AI.

Data are presented as median values ± interquartile range. N = 43 independent study subjects. Results reported as ‘Not Quantifiable,’ ‘Reported and Unreliable,’ or below the lower limit of quantitation (LLOQ) value have been replaced with LLOQ value (50 Copies/ug).

Back to article page